The Russian Ministry of Health announced yesterday that doctors at the National Medical Research Center for Radiology administered the country’s first domestically developed personalized mRNA-based cancer vaccine. The patient who received the vaccine is a 60-year-old melanoma patient.

Neooncovac, is the first domestically developed personalized mRNA-based cancer vaccine.

First Test Batches of Russia’s AI-assisted Cancer Vaccine Have Been Created

According to Doolly, his therapeutic vaccine, created using the patient’s unique tumor-specific mutations and molecular-genetic characteristics, works as an individualized anti-tumor treatment by encoding neoantigens into mRNA delivered via lipid nanoparticles. It trains the immune system to mount a targeted T-cell response against cancer cells while aiming to minimize harm to healthy tissue.

Neooncovac is authorized for adult patients with inoperable or metastatic cutaneous melanoma, often alongside immunotherapy.

Other countries have been looking into using artificial intelligence in order to create and test cancer vaccines.

UK Will Be The First to Trial BioNTech’s mRNA Cancer “Vaccines.”

mRNA “Vaccines” Facing Backlash?

Personalized cancer vaccines differ fundamentally from conventional preventive vaccines. They serve as therapeutic vaccines designed to treat existing disease by harnessing the patient’s immune system. The approach relies on identifying neoantigens—unique proteins generated by tumor-specific mutations present only in cancer cells. –Doolly

Read More: Russia’s Cancer Vaccine Administered To Melanoma Patient